Preclinical study of influenza virus a M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys

Vaccine

Volumn 22, Issue 23-24, 2004, Pages 2993-3003

  Fan, Jiang ^a   Liang, Xiaoping ^a   Horton, Melanie S ^a   Perry, Helen C ^a   Citron, Michael P ^a   Heidecker, Gwen J ^a   Fu, Tong Ming ^a   Joyce, Joseph ^a   Przysiecki, Craig T ^a   Keller, Paul M ^a   Garsky, Victor M ^a   Ionescu, Roxana ^a   Rippeon, Yvette ^a   Shi, Li ^a   Chastain, Michael A ^a   Condra, Jon H ^a   Davies, Mary Ellen ^a   Liao, Jason ^a   Emini, Emilio A ^a   Shiver, John W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Influenza virus vaccine; M2; OMPC conjugate

Indexed keywords

FLUZON; INFLUENZA VACCINE; MEMBRANE PROTEIN; PROTEIN M2; QS 21; RECOMBINANT PROTEIN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG POTENCY; DRUG SCREENING; DRUG TARGETING; EXPERIMENTAL MODEL; EXTRACELLULAR MATRIX; FEMALE; FERRET; IMMUNOGENICITY; IMMUNOREACTIVITY; INFLUENZA VACCINATION; LETHALITY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROVOCATION TEST; RHESUS MONKEY; STATISTICAL SIGNIFICANCE; TECHNIQUE; VIRUS RECOMBINATION; VIRUS SHEDDING; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; BACTERIAL OUTER MEMBRANE PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRETS; HEMOCYANIN; INFLUENZA A VIRUS; INFLUENZA VACCINES; LUNG; MACACA MULATTA; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NASAL MUCOSA; NEISSERIA MENINGITIDIS; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, CONJUGATE; VACCINES, SUBUNIT; VIRUS REPLICATION;

EID: 3843069907     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.02.021     Document Type: Article

References (32)

1. Simonsen L., Fukuda K., Schonberger L.B., Cox N.J. The impact of influenza epidemics on hospitalizations. J Infect Dis. 181:2000;831-837
2. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N.J., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 289:2003;179-186
3. Simonsen L., Clarke M.J., Schonberger L.B., Arden N.H., Cox N.J., Fukuda K., et al. Prevention and early treatment of influenza in healthy adults. Vaccine. 18:2000;957-1030
4. Wilde J.A., McMillan J.A., Serwint J., Butta J., O'Riordan M.A., Steinhoff M.C. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA. 281:1999;908-913
5. Bridges C.B., Thompson W.W., Meltzer M.I., Reeve G.R., Talamonti W.J., Cox N.J., et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA. 284:2000;1655-1663
6. Lamb R.A., Zebedee S.L., Richardson C.D. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell. 40:1985;627-633
7. Sugrue R.J., Hay A.J. Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology. 180:1991;617-624
8. Holsinger L.J., Lamb R.A. Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology. 183:1991;32-43
9. Holsinger L.J., Nichani D., Pinto L.H., Lamb R.A. Influenza A virus M2 ion channel protein: a structure-function analysis. J Virol. 68:1994;1551-1563
10. Shimbo K., Brassard D.L., Lamb R.A., Pinto L.H. Ion selectivity and activation of the M2 ion channel of influenza virus. Biophys J. 70:1996;1335-1346
11. Takeda M., Pekosz A., Shuck K., Pinto L.H., Lamb R.A. Influenza a virus M2 ion channel activity is essential for efficient replication in tissue culture. J Virol. 76:2002;1391-1399
12. Helenius A. Unpacking the incoming influenza virus. Cell. 69:1992;577-578
13. Treanor J.J., Tierney E.L., Zebedee S.L., Lamb R.A., Murphy B.R. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol. 64:1990;1375-1377
14. Slepushkin V.A., Katz J.M., Black R.A., Gamble W.C., Rota P.A., Cox N.J. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine. 13:1995;1399-1402
15. Frace A.M., Klimov A.I., Rowe T., Black R.A., Katz J.M. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine. 17:1999;2237-2244
16. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med. 5:1999;1157-1163
17. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys. 82:1959;70-79
18. Shuler K.R., Dunham R.G., Kanda P. A simplified method for determination of peptide-protein molar ratios using amino acid analysis. J Immunol Methods. 156:1992;137-149
19. Leanza W.J., Chupak L.S., Tolman R.L., Marburg S. Acidic derivatives of homocysteine thiolactone: utility as anionic linkers. Bioconjug Chem. 3:1992;514-518
20. Riddles P.W., Blakeley R.L., Zerner B. Reassessment of Ellman's reagent. Methods Enzymol. 91:1983;49-60
21. Donnelly J.J., Friedman A., Martinez D., Montgomery D.L., Shiver J.W., Motzel S.L., et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med. 1:1995;583-587
22. Reed L.J., Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg. 27:1938;493-497
23. Nedrud J.G., Liang X.P., Hague N., Lamm M.E. Combined oral/nasal immunization protects mice from Sendai virus infection. J Immunol. 139:1987;3484-3492
24. Diggle PJ, Liang KY, Zeger SL. Analysis of longitudinal data. New York: Oxford University Press; 1994.
25. McCullagh P, Nelder JA. Generalized linear models. New York: Chapman and Hall; 1989.
26. Macken C, Lu H, Goodman J, Boykin L. The value of a database in surveillance and vaccine selection. In: Osterhaus ADME, Cox N, Hampson AW, editors. Options for the control of influenza IV. Amsterdam: Elsevier; 2001. p. 103-6.
27. Kniskern P.J., Marburg S., Ellis R.W. Haemophilus influenzae type b conjugate vaccines. Pharm Biotechnol. 6:1995;673-694
28. Mozdzanowska K., Feng J., Eid M., Kragol G., Cudic M., Otvos L., et al. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine. 21:2003;2616-2626
29. Liu W., Li H., Chen Y.H. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol Med Microbiol. 35:2003;141-146
30. Liu G., Anderson C., Scaltreto H., Barbon J., Kensil C.R. QS-21 structure/function studies: effect of acylation on adjuvant activity. Vaccine. 20:2002;2808-2815
31. Evans T.G., McElrath M.J., Matthews T., Montefiori D., Weinhold K., Wolff M., et al. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine. 19:2001;2080-2091
32. Claas E.C., Osterhaus A.D., van Beek R., De Jong J.C., Rimmelzwaan G.F., Senne D.A., et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet. 351:1998;472-477